MBOT vs UNH

Microbot Medical remains a high-risk, high-reward proposition with compelling 10x potential in the robotic endovascular surgery market. The significant milestone of reporting first LIBERTY commercial revenue in Q1 2026, coupled with the transition to Full Market Release and recent regulatory approval in Israel, marks substantial progress in validating its strategic vision and technology. These dev...

UnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company...